Authors
Latest:
What the Age of Multi-Localism Means for PharmaNew realities are transforming the global environment and upending a business model based on the presumption of ever more connected markets. Paul A. Laudicina asks, What does this new age mean for pharma?
Latest:
Driving Access to the Most Efficient Form of HealthcareA look at the pharmaceutical value chain and how pricing concerns and patient centricity fits in to improving access.
Latest:
Curing Big Pharma’s Litigation Spend Woes with Data-Driven MedicineDaniel Gold looks at the benefits of centralising an organization's data in a core repository and adopting a comprehensive business intelligence strategy.
Latest:
Creating Defensible Data Analytics Moats for a Competitive AdvantageKarim Damji discusses how Artificial Intelligence (AI)-informed Systems of Intelligence and Virtual Assistants offer powerful solutions to the common struggles pharma companies face today.
Latest:
Social Science Behavior Change Models: The Key to More Targeted MessagesBehavioral social scientists try to understand human behavior and find ways to make people accept and adapt it. Pharma sales and marketing is no different – especially with the launch of a new product, writes Charles Daramola.
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
The Genetic Data Gold Rush: Balancing Privacy and Health OutcomesAs pharm execs look to real-world data to aid in translational research and close the gap from traditional clinical trials to real-world efficacy, there are three foundational pillars to build from. Bill Fox reports.
Latest:
The Future of JAK InhibitorsPharma companies have faced hurdles in gaining approval of Janus kinase (JAK) inhibitors for the treatment of rheumatoid arthritis. Denise Baldock, Elizabeth Baynton, Amanda Baskett, and Nicola Bailey look at what can be learned from the lessons of the past.
Latest:
Advocacy and Access in a Complex MarketplaceNick Hicks and Bruno Santoni explore the complex plasma-derived medical products marketplace.
Latest:
Patent Protection for Cannabis?Amid a still-difficult environment for enforcing cannabis-related patents, this article explores some of the types of patent protection available for cannabis-based therapies and inventions.
Latest:
Patent Protection for Cannabis?Amid a still-difficult environment for enforcing cannabis-related patents, this article explores some of the types of patent protection available for cannabis-based therapies and inventions.
Latest:
In Blockchain We TrustThe next generation of supply chain shows an increasing need for blockchain technology.
Latest:
Is the Price Right? An Overview of US Pricing StrategiesBruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.
Latest:
Bribery and Corruption Compliance in UK Pharma: Where Are We Now?When it first came into force the UK Bribery Act 2010 was deemed to be revolutionary. Looking back, what has been its impact on pharma? Chris Cartmell and Jo Pisano report.
Latest:
FDA's $100 Million RWE Project: Making It All It Can BeFDA's proposal to build a modern system to gather real-world evidence (RWE) from about 10 million individuals could have profound implications, but it will realize its potential only if FDA takes a more expansive view of what RWE can be, writes Paul Glimcher.
Latest:
RMAT Designations: Lessons Learned on the “Clinical Evidence” RequirementThe Regenerative Medicine Advanced Therapies (RMAT) designation was introduced by the 21st Century Cures Act as a pathway to accelerate FDA approval and market entry of regenerative medical therapies. Two years on, William Rose and Suchira Ghosh identify the trends in how FDA assesses the clinical evidence supporting successful RMAT candidates.
Latest:
Pharmacovigilance Software's “Salesforce” MomentAlthough it is unlikely that mock demonstrators will be seen at any drug information or regulatory conferences, pharmacovigilance software is indeed having its “Salesforce” moment.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Trust—Biotech’s Hidden AdvantageHow companies can trust now to cultivate corporate reputations that build business.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Diabetes Researchers Make Novel Connections with Graph TechnologyEmil Eifrem examines how life science researchers at Munich’s German Center for Diabetes Research are uncovering insights in their data with a new way of working with complex data
